Driving Concepts of Cardiovascular (CV) Nuclear Imaging in the Current Era & Update on CV Molecular Imaging 2011

Saturday, June 4 | 8:00 AM - 12:00 PM
Ballroom C2

Objectives
Upon completion of this activity, the participant will be able to:
1. Discuss key concepts that are predicted to drive the clinical utility of cardiovascular nuclear medicine in the current era.
2. Explain the impact of cost constraints.
3. Identify risks and benefits of radionuclide cardiovascular imaging.
4. Discuss current concepts of vascular molecular imaging.

Speakers are:
Mehran M. Sadeghi, MD, Yale University School of Medicine in New Haven, Conn.;
Ronald G. Schwartz, MD, University of Rochester Medical Center in Rochester, N.Y.;
Robert A. deKemp, PhD, University of Ottawa Heart Institute in Ottawa, Ontario;
Marcelo F. Di Carli, MD, Brigham & Women's Hospital in Boston;
Jamshid Maddahi, MD, University of California, Los Angeles;
H. William Strauss, MD, Memorial Sloan Kettering Cancer Center & Memorial Hospital in New York City; and
Daniel S. Berman, MD, Cedars-Sinai Medical Center in Los Angeles.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.